Angiodynamics' apex-av trial results assessing alphavac f18⁸⁵ system in treatment of pulmonary embolism presented at scai 2024 scientific sessions

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the acute pulmonary embolism extraction trial with the alphavac system (apex-av) were presented at the society for cardiovascular angiography & interventions (scai) 2024 scientific sessions hos.
ANGO Ratings Summary
ANGO Quant Ranking